Ascletis Pharma Inc. (ASCLETIS-B) has awarded 1.80 million share options to 42 employees under its 2025 Share Option Scheme. The grant was approved on 4 November 2026 and represents a fresh long-term incentive component within the company’s remuneration framework.

Key terms of the grant: • Exercise price: HK$4.923 per share, a 7.8% premium to the HK$4.565 closing price on the grant date. • Vesting: Five equal tranches of 360,000 options each, becoming exercisable annually from 4 November 2027 through 4 November 2031. • Expiry: 10 years from the grant date, ending 3 November 2036. • Participants: 42 employee grantees; none is a director, chief executive, substantial shareholder, related entity participant or service provider as defined by HKEX listing rules. • Scheme headroom: Following this issuance, 31.29 million shares remain available for future grants under the 2025 Share Option Scheme.

The board states the options are intended to supplement cash compensation, foster long-term commitment, and align employee interests with the company’s growth trajectory. Each option is subject to standard clawback provisions, including lapse upon cessation of employment or contractual breaches.